Evidence map›Paper›PMID 33502499›Full record

ArticleRheumatology (Oxford, England)2021

Baricitinib set to join the Covid-19 therapeutic arsenal?

Tania Gudu, Carmel Stober, Andrew P Cope, Joseph Cheriyan, James Galloway, Ian B Wilkinson, Michalis Kostapanos, David Jayne, Frances Hall

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Tania GuduRheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Carmel StoberRheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Andrew P CopeCentre for Rheumatic Disease, King's College London, London, UK.
Joseph CheriyanCambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, , Cambridge, UK.
James GallowayCentre for Rheumatic Disease, King's College London, London, UK.
Ian B WilkinsonCambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, , Cambridge, UK.
Michalis KostapanosDivision of Experimental Medicine & Immunotherapeutics, School of Clinical Medicine, University of Cambridge, , Cambridge, UK.
David JayneDepartment of Medicine, University of Cambridge, Cambridge, UK.
Frances HallRheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Funding

Medical Research Council MC_PC_20006
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AzetidinesCOVID-19COVID-19 Drug TreatmentPurinesPyrazolesSulfonamidesAntiviral AgentsClinical Trials as TopicHumansImmunologic FactorsIntracellular Signaling Peptides and ProteinsJanus Kinase InhibitorsProtein Serine-Threonine KinasesSARS-CoV-2Treatment OutcomeAAK1 protein, humanAntiviral AgentsAzetidinesbaricitinibGAK protein, humanImmunologic FactorsIntracellular Signaling Peptides and ProteinsJanus Kinase InhibitorsProtein Serine-Threonine KinasesPurinesPyrazolesSulfonamides

Identifiers

PMID33502499
PMCPMC7928625

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.